Neurological Institute Outcomes
Brain Tumors
Stereotactic Radiosurgery: Gamma Knife
The 30- and 180-day survival rates after Gamma Knife® radiosurgery were 100% and 99%, respectively, for 2020; 838 Gamma Knife procedures were done.
Gamma Knife Radiosurgery: Survival by Tumor Type – Meningioma
2016 – 2020
Both the 30- and 180-day survival rates after Gamma Knife radiosurgery for meningioma in 2020 were 100%.
Gamma Knife Radiosurgery: Survival by Tumor Type – Schwannoma
2016 – 2020
Both the 30- and 180-day survival rates after Gamma Knife radiosurgery for Schwannoma in 2020 were 100%.
Gamma Knife Radiosurgery: Survival by Tumor Type – Pituitary
2016 – 2020
Both the 30- and 180-day survival rates after Gamma Knife radiosurgery for pituitary tumors in 2020 were 100%.
Gamma Knife Radiosurgery: Survival by Tumor Type – Metastasis
2016 – 2020
Both the 30- and 180-day survival rates after Gamma Knife radiosurgery for brain metastasis in 2020 were 100%.
Gamma Knife Radiosurgery: Karnofsky Performance Scale (N = 152)
2020
Functional status is measured by the Karnofsky Performance Scale, a widely used 11-point scale correlating to percentage values from 100% (no evidence of disease, no symptoms) to 0% (death). In 90% of patients, performance status remained stable or improved after stereotactic radiosurgery. Change in status was defined as a change of ≥ 20 points.
Survival: Gamma Knife Stereotactic Radiosurgery
2016 – 2020
The 30- and 180-day survival rates after Gamma Knife radiosurgery were 100% and 99%, respectively, for 2020; 838 Gamma Knife procedures were done.
